166 related articles for article (PubMed ID: 35843439)
1. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
2. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
Hayes W; Sas DJ; Magen D; Shasha-Lavsky H; Michael M; Sellier-Leclerc AL; Hogan J; Ngo T; Sweetser MT; Gansner JM; McGregor TL; Frishberg Y
Pediatr Nephrol; 2023 Apr; 38(4):1075-1086. PubMed ID: 35913563
[TBL] [Abstract][Full Text] [Related]
4. Lumasiran: A Review in Primary Hyperoxaluria Type 1.
Kang C
Drugs; 2024 Feb; 84(2):219-226. PubMed ID: 38252335
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Sas DJ; Magen D; Hayes W; Shasha-Lavsky H; Michael M; Schulte I; Sellier-Leclerc AL; Lu J; Seddighzadeh A; Habtemariam B; McGregor TL; Fujita KP; Frishberg Y;
Genet Med; 2022 Mar; 24(3):654-662. PubMed ID: 34906487
[TBL] [Abstract][Full Text] [Related]
7. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Hulton SA; Groothoff JW; Frishberg Y; Koren MJ; Overcash JS; Sellier-Leclerc AL; Shasha-Lavsky H; Saland JM; Hayes W; Magen D; Moochhala SH; Coenen M; Simkova E; Garrelfs SF; Sas DJ; Meliambro KA; Ngo T; Sweetser MT; Habtemariam BA; Gansner JM; McGregor TL; Lieske JC
Kidney Int Rep; 2022 Mar; 7(3):494-506. PubMed ID: 35257062
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Martin-Higueras C; Borghese L; Torres A; Fraga-Bilbao F; Santana-Estupiñán R; Stefanidis CJ; Tory K; Walli A; Gondra L; Kempf C; Gessner M; Habbig S; Eifler L; Schmitt CP; Rüdel B; Bartram MP; Beck BB; Hoppe B
Kidney Int Rep; 2024 Jan; 9(1):114-133. PubMed ID: 38312792
[TBL] [Abstract][Full Text] [Related]
9. Lumasiran for primary hyperoxaluria type 1: What we have learned?
Gang X; Liu F; Mao J
Front Pediatr; 2022; 10():1052625. PubMed ID: 36704142
[TBL] [Abstract][Full Text] [Related]
10. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.
Hoppe B; Pellikka PA; Dehmel B; Banos A; Lindner E; Herberg U
Nephrol Dial Transplant; 2021 Jul; 36(8):1464-1473. PubMed ID: 32810261
[TBL] [Abstract][Full Text] [Related]
11. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.
Méaux MN; Sellier-Leclerc AL; Acquaviva-Bourdain C; Harambat J; Allard L; Bacchetta J
Pediatr Nephrol; 2022 Apr; 37(4):907-911. PubMed ID: 35015123
[TBL] [Abstract][Full Text] [Related]
12. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.
Sas DJ; Mara K; Mehta RA; Seide BM; Banks CJ; Danese DS; McGregor TL; Lieske JC; Milliner DS
Pediatr Nephrol; 2024 Jan; 39(1):141-148. PubMed ID: 37458799
[TBL] [Abstract][Full Text] [Related]
13. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.
Hillebrand P; Hoppe B
Pediatr Nephrol; 2020 Jul; 35(7):1227-1233. PubMed ID: 32274573
[TBL] [Abstract][Full Text] [Related]
14. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
Milliner D; Hoppe B; Groothoff J
Urolithiasis; 2018 Aug; 46(4):313-323. PubMed ID: 28718073
[TBL] [Abstract][Full Text] [Related]
15. Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.
Taroni F; Peruzzi L; Longo G; Becherucci F; Malgieri G; D'Alessandro MM; Montini G
Clin Kidney J; 2024 May; 17(5):sfae090. PubMed ID: 38742209
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1.
Chiodini B; Tram N; Adams B; Hennaut E; Lolin K; Ismaili K
Front Pediatr; 2021; 9():791616. PubMed ID: 35071135
[No Abstract] [Full Text] [Related]
17. Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males.
Aldabek K; Grossman OK; Al-Omar O; Fox JA; Moritz ML
Cureus; 2022 Jan; 14(1):e21673. PubMed ID: 35237473
[TBL] [Abstract][Full Text] [Related]
18. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease.
Perinpam M; Enders FT; Mara KC; Vaughan LE; Mehta RA; Voskoboev N; Milliner DS; Lieske JC
Clin Biochem; 2017 Dec; 50(18):1014-1019. PubMed ID: 28764885
[TBL] [Abstract][Full Text] [Related]
19. Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside.
D'Ambrosio V; Ferraro PM
Int J Nephrol Renovasc Dis; 2022; 15():197-206. PubMed ID: 35747094
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
